Sanodyne Therapeutics, Inc. (Headquarters: Chuo-ku, Tokyo; Representative: Ryota Sakurai; hereinafter “the Company”) is pleased to announce that at the Extraordinary　Shareholders’ meeting held on April 1, 2026, Hideki Hirabayashi was newly elected as a Director as of May 1, 2026. Concurrently, Dr. Hirabayashi will assume the position of Executive Director and CSO of the Company.

  The Company also announces that Kazuhiko Nonomura, who has served as Co-Representative Director alongside Ryota Sakurai, has stepped down from his role as Representative Director and assumed the position of Director. Dr. Nonomura will continue to strive to enhance the Company’s corporate value as an external Director dispatched by our investors.

  Following these changes, the Company’s new management structure is as follows:

Representative Director & CEO: Ryota Sakurai
Executive Director & CSO: Hideki Hirabayashi
Director: Takuma Tsuzuku (JIC Venture Growth Investments)
Director: Kazuhiko Nonomura (RDiscovery)

Under the new management structure, the Company will further accelerate the research and development of its lead asset, SNT-001, to deliver it to patients suffering from peripheral neuropathy and neuropathic pain.

[Contact Information]
Sanodyne Therapeutics, Inc.
https://sanodyne.com/contact/